About
Dangerous viruses pose a global, persistent and unavoidable threat to humanity.
What if we could predict which variants of a virus are of greatest concern and design medicines to protect against them, a priori?
Many of the world’s most threatening viruses are continually evolving, outwitting our immune systems, outpacing efforts to develop new effective medicines and causing untold human suffering.
Our pioneering approach centers on a unique technology platform which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants.
Founded by Flagship Pioneering, Apriori is a leading health security company with a mission to provide humanity with variant-proof protection against rapidly-evolving viruses.
Team
Balint Antal, PhD
Senior Scientist
.jpg)
Sukhmani Bedi, PhD
Scientist II
Charlens Beneche
Research Associate II
Yvonne Chan, PhD
Senior Scientist
Julia Chartove, PhD
Scientist II
David Chiovitti
Scientist II
Gus Dunn, PhD
Associate Director
Jack Holland, PhD
Scientist
Anna Honko, PhD
Director of Preclinical Biology
Christine Isabella, PhD
Scientist II
Patrick Jones, PhD, MBA
Head of R&D Strategy
Dina Magner
Senior Research Associate II
Crystal Mendoza-Lopez, PhD
Scientist
Diego Mourao, PhD
Senior Scientist II
Al Swiston, PhD
Head of Data Science
Caroline Wilkinson
Senior Engineer
.jpeg)
